2017.Jun.01

OBI Pharma Announces Acquisition of the Novel First-in-class Anti-Cancer Drug OBI-3424 from Threshold Pharmaceuticals to be Developed as Potential Anti-Cancer Therapy for Cancers with High AKR1C3

Date of occurrence: June 01, 2017 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): N/A Reciprocal shareholding ratios: N/A Name of mass media: China Times E-Paper Content reported: OBI Pharma (4174) announced the in-licensing of the novel first-in-class small molecule drug TH-3424 from California Threshold Pharmaceuticals. The […]

HOMEWhat’s NewAnnouncementsOBI Pharma Announces Acquisition of the Novel First-in-class Anti-Cancer Drug OBI-3424 from Threshold Pharmaceuticals to be Developed as Potential Anti-Cancer Therapy for Cancers with High AKR1C3

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2017.Apr.26

Announcement of explanation on the first instance judgment of the civil action between the Company against "Next Magazine"

2017.Jun.11

Supplemental information on the approved application of Phase III clinical trial of OBI-822, the novel breast cancer drug, in China, US, and the EU